Few publications exist regarding gadolinium-enhanced sequences in rectal MRI. None have evaluated its potential impact on patient management.
cularization. To complicate matters, GAD may enhance normal tissue because of changes induced by chemoradiotherapy. [1] [2] [3] Several publications have shown no clear advantage of GAD in T-staging MRI examinations for rectal cancer, [4] [5] [6] [7] and recent European Society of Gastrointestinal and Abdominal Radiology guidelines do not recommend its use. However, GAD is still used routinely at many institutions in both baseline (BL) and postneoadjuvant settings.
Most previous publications on the use of GAD in rectal MRI have evaluated changes in diagnostic staging accuracy. In a study of 83 patients with rectal cancer, the use of GAD did not yield improved accuracy over T2-weighted images in detecting tumor penetration through the rectal wall or tumor extension into mesorectal fascia. 4 In a study of preoperative assessments of 88 patients with rectal cancer, for a comparison of area under the curve values in ROC analysis of T2 only, T1 plus GAD only, and combined T2 and T1 plus GAD for 2 readers, no significant differences in diagnostic accuracy were observed for tumor or nodal staging. 5 In another retrospective study of 72 patients with advanced rectal cancer, the use of combined T2 and T1 plus GAD-weighted sequences versus T2 alone yielded no advantage in interobserver agreement, accuracy in determining T category, or involvement of surrounding organs. 8 Some centers also perform dynamic contrast-enhanced (DCE) sequences. Evidence for the use of DCE is conflicting, with some authors suggesting a role in predicting complete pathological response. [9] [10] [11] To our knowledge, no studies have evaluated the contribution of GAD at BL or after neoadjuvant treatment (either static or DCE sequences) to changes in radiologic T staging, measurement of specific tumor margins, and, more importantly, its potential impact on management of patients with rectal cancer. Clarification of the influence of GAD during MRI could impact medical and surgical management, particularly in view of the increased use of MRI in lieu of endorectal ultrasound. Furthermore, its use incurs added magnet time and cost per patient, as well as occasional morbidity, including allergy, nephrogenic systemic fibrosis, and GAD accumulation in the brain. [12] [13] [14] [15] The purpose of this study was to assess whether GAD use (especially using DCE-MRI) changes radiologic T stage or tumor relationship to surrounding structures at BL and/or postneoadjuvant treatment MRI for primary rectal cancer and whether use of GAD could alter the overall treatment plan at BL and/or the surgical approach of recommended postneoadjuvant chemoradiotherapy.
PATIENTS AND METHODS

Demographics
Approval was obtained from the Memorial Sloan Kettering Cancer Center Institutional Review Board for retrospective analysis of collected data in this study. All of the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5) . For this type of study, formal consent is not required.
A retrospective search of the institutional database identified the 100 most recent consecutive rectal MRIs, between December 2011 and January 2015. Inclusion criteria were patients with histologically proven rectal adenocarcinoma who underwent pretreatment (BL) MRI and/ or after total neoadjuvant treatment MRI. Total neoadjuvant treatment was defined as completion of induction chemotherapy followed by chemoradiotherapy (n = 40), chemoradiotherapy alone (n = 7), or chemotherapy alone (n = 3). Exclusion criteria were patients operated on by the surgical coauthor, metastatic disease at time of diagnosis, poor-quality MRI, and lack of DCE sequences.
The final cohort included 66 patients (mean age = 59.0 y; range, 29.2-84.9 y). Thirty four had both BL (mean age = 55.5 y; range, 29.2-81.1 y) and posttreatment (PNT) scans (mean age = 56.5; range, 29.5-84.9 y). Sixteen patients had only BL scans, and an additional 16 had only PNT scans. In total, 50 studies of BL-staging MRI and 50 of PNT-restaging MRI were examined.
MRI Protocols
MRI examinations were performed on different MRI scanners manufactured by GE Healthcare (Waukesha, WI) at a field strength of 1.5-or 3.0-T using a standardized MRI protocol that included standard high-resolution T2-weighted imaging in axial, sagittal, coronal, and oblique orientation (time of repetition (TR) = 4400-5000; time of echo (TE) = 90-110; echo train length = 12-24; section thickness = 3-4 mm; interslice gap = 1 mm; field of view (FOV) = 20 cm; matrix: 320 × 160; Number of Excitations (NEX) = 2); an axial diffusion-weighted sequence (singleshot, spin-echo EPI sequence; b values = 0 and 750-1,000 s/ mm 2 ; TR = 1800-5550 ms; TE = 60-112 ms; section thickness = 3-5 mm; interslice gap = 1 mm; FOV = 18-40 cm; matrix = 96-256 × 96-128; NEX = 3-6; mean acquisition time = 2.4 min); and sagittal DCE-MRI sequence (TR = 3.1-7.9 ms; TE = 0.9-4.2 ms; section thickness = 4-10 mm; no interslice gap; FOV = 20-34 cm; matrix = 256-320 × 128-192; mean temporal resolution = 8.3 s (5.0-11.5 s); 30-40 phases; mean acquisition time = 5.2 min). A bolus of gadolinium-diethylenetriamine pentaacetic acid (Magnevist, Bayer Schering, Berlin-Wedding, Germany) at a constant dose of 0.1 mmol/kg was power injected at a rate of 2 mL/s followed by a saline flush for all of the patients. After the DCE sagittal sequence, a standard axial postgadolinium-diethylenetriamine pentaacetic acid spoiled 3-dimensional gradient echo sequence was obtained (liver acquisition with volume acceleration; breath-hold; TR = default; TE = in phase; section thickness = 3 mm; no gap; FOV = 28-36 cm; 320 × 192; NEX = 1).
Radiologic Interpretation
Two board-certified radiologists retrospectively interpreted MRI while blinded to details of clinical history for each case. Observer 1 was an academic senior radiologist subspecializing in GI oncologic radiology. Observer 2 was a junior radiologist with fellowship training in oncologic radiology. Observer 1 interpreted BL cases only and observer 2 interpreted PNT only. For BL and PNT readings, MRI cases were interpreted twice, first using the T2-weighted sequence alone (GAD-) and subsequently <48 hours later with T1-weighted GAD (GAD+) sequences (combined spoiled gradient echo (static) plus DCE). For each study, the radiologist recorded T stage, distance from the inferior tumor border to the anal verge (AV), distance from the inferior tumor border to sphincter apparatus/anorectal ring (ARR), and distance to mesorectal fascia (circumferential resection margin). The relationships to the anterior peritoneal reflection (above, below, and straddles), sphincter involvement, and tumor size (craniocaudal length and thickest wall) were also recorded at BL.
Clinical/Surgical Interpretation
Radiologic interpretations were systematically and anonymously presented to the single experienced surgeon who did not operate on any case in 4 sessions, separated by ≥4 weeks, along with a clinical history proforma for clinical management assessment. The surgeon was blinded to whether radiologic interpretations provided were GADor GAD+.
The proforma contained chief symptom, history of present illness, physical examination, digital rectal examination, laboratory work, medications, Eastern Cooperative Oncology Group performance score, 16 colonoscopy and images, biopsy, endorectal ultrasound, and results of other imaging studies. Clinical proformas for PNT cases revealed the actual treatment and clinical course up to the time of PNT MRI.
For BL MRI interpretations, the surgeon selected a theoretical initial treatment plan, including direct to surgery, preoperative treatment (induction/chemoradiation therapy), palliative treatment, or nonoperative management. For PNT MRI interpretations, the surgeon selected a theoretical PNT surgical plan, including no surgery (nonoperative management or inoperable), transanal excision, total mesorectal excision, low anterior resection, abdominoperineal resection, intersphincteric resection, exenteration, or other.
Definitions and Criteria
Radiologic T stage was reported according to the 7 th edition American Joint Committee on Cancer system. Current surgical recommendations at our institution for T1/ T2 tumors are to proceed directly to surgery with either transanal excision or total mesorectal excision, unless there are suspicious lymph nodes or tumor is adjacent to the sphincter apparatus. For T3 and T4 tumors, patients are recommended for long-course chemoradiotherapy often with induction chemotherapy followed by surgery. 17 Clinical complete response was defined as having no residual tumor present on PNT imaging and no mass on digital rectal examination and/or endoscopy.
Statistics
Differences in GAD-and GAD+ radiologic interpretations were analyzed using the Student paired t test, 2-tailed, for all continuous variables. Descriptive statistics and frequency distribution were conducted for T stage. Differences in treatment plans rendered based on GAD-versus GAD+ were reported using descriptive statistics. Statistics were conducted using GraphPad Prism 7 (GraphPad Software, La Jolla, CA) and SPSS software (IBM Corp, Armonk, NY). A p value of 0.05 was selected to determine significance with a CI of 95%.
RESULTS
Clinical and Pathologic Tumor Stages
For the 100 cases (50 BL and 50 PNT), the distribution of clinical tumor and node stage, posttreatment pathologic tumor and node stages, and actual treatment received are detailed in Table 1 .
MRI Reading Baseline
Results of tumor stage are reported in Figure 1 . Table 2 details the changes using GAD+ for tumor height, size, and distance to mesorectal fascia. At BL, differences in distances to AV, ARR, and MRF, as well as wall thickness and tumor size, were not statistically significant (Table 2) .
Posttreatment
Results of PNT tumor stage are reported in Figure 1 . Tstage changes occurred in 2% (1/50) with use of GAD+, with upstaging from T1/2 to T3a. Statistically significant differences were found in measurements of distance to the AV (p = 0.0017) and to the anorectal ring (p = 0.0151) with GAD+, depicted in Table 3 .
For PNT cases, a comparison with the gold-standard pathologic stage was conducted. Pathologic stage data were unavailable for 12 (24%) of 50 patients, who underwent nonoperative management. Eight of these 12 were clinical complete responses, 2 refused surgery, and 2 did not undergo surgery because of extensive disease or significant cardiac comorbidity. For 29 (76%) of 38 patients, both GAD-and GAD+ accurately assessed T stage. For 5 (13%) of 38 patients, both GAD-and GAD+ overstaged tumors, and for 3 (8%) of 38, both understaged tumors. For 1 of 38 patients, GAD-accurately assessed a T1/2 tumor, whereas GAD+ overstaged it as T3.
Changes in Treatment Planning
Baseline At BL, 12 total T-stage changes occurred with GAD. However, changes in BL treatment planning only occurred for 4 of these 12 changes, 3 T upstages and 1 T downstage (Table 4) . Because of upstaging from T1/2 (with no nodes) to T3a (n = 2) or T3b (n = 1), these patients were recommended for chemoradiotherapy (CRT), per our reviewing surgeon and our institutional treatment standards. Because 1 case downstaged from T3b to T1/2 (with no nodes), the patient was recommended for surgery directly rather than preoperative CRT. Figure 2 depicts 2 cases in which changes in radiologic T stage and corresponding changes in treatment plans were rendered with GAD.
Using quantitative analysis instead of numerical means, which did not differ statistically with GAD, in 7 cases, the differences were clinically significant enough to warrant a change in treatment (Table 4 ). Relationships to the anterior peritoneal reflection (n = 4), anorectal ring (n = 2), or AV (n = 1) accounted for treatment changes. In 3 cases of stage T1/2 rectal cancer not requiring CRT, radiation for tumor shrinkage was no longer warranted with use of GAD because the tumor was measured as farther from the sphincters, thus not requiring downstaging for sphincter preservation. In 1 case the tumor was interpreted as above the anterior peritoneal reflection, also a relative contraindication for radiation. In the remaining 3 cases, the tumor changed from above to below the anterior peritoneal reflection, thus instead of a direct-to-surgery plan, CRT was recommended. Figure 3 depicts a BL case that demonstrates improved delineation of the anterior peritoneal reflection with GAD.
Posttreatment
Changes in PNT readings occurred in 2% (1/50) with use of GAD, with upstaging from T2 to T3a. Because this patient had already received treatment and did not have a major stage change, there was no resultant change in treatment.
Although statistically different measurements of distance from the inferior tumor border to AV (p = 0.0017) and to ARR (p = 0.0151) were observed with GAD, no clinically significant changes were noted that altered treatment as recommended by our reviewing surgeon, because patients already qualified for neoadjuvant treatment. GAD did not result in clinically significant alterations in tumor location with respect to the anterior peritoneal reflection, ARR, or AV to warrant a change in surgical approach. Overall, discordant treatment assessments were made in 11 patients, all at BL, 4 because of changes in radiologic T stage with GAD and 7 because of tumor height in the rectum.
DISCUSSION
In this retrospective study of patients with rectal cancer who were imaged by MRI with GAD per our institutional standard of care and interpreted blindly with and without GAD sequences, the use of GAD in BL MRI altered T staging in 24% of cases. These changes would not have altered treatment in the majority of these cases because of nodal status. Of greater impact was the change in location of tumor using GAD, wherein treatment in 7 patients would still have changed. At PNT, only 1 T stage change occurred with GAD, and this would not have affected treatment. Although significant differences were noted in average distances to the AV and ARR using GAD, no individual case resulted in a change in treatment, and thus GAD had no potential effect on patient management in the PNT setting.
Although the clinical consequence of stage T2 versus T3a with a clear circumferential resection margin alone might not necessarily indicate a change in treatment based on current guidelines, neoadjuvant CRT can be administered for locally advanced cancer (cT3 or T4) to increase the probability of sphincter-preserving resections, which is recommended at our institution, as compared with patients with T2 tumors who are recommended for direct surgery. It is also important to consider that additional factors in conjunction with stage could also contribute to the decision for CRT versus direct surgical intervention, such as nodal status and tumor location/proximity to sphincters, as well as circumferential resection margin involvement.
Because T stage changes using GAD at BL showed no consistent pattern, little could be concluded in our small study. Nonetheless, more cases were downstaged than upstaged after GAD. We believe that this is because tumors perfuse and de-enhance with GAD earlier than normal tissue. The de-enhanced tumor allowed better definition of its borders as low signal intensity not ex- Results are from paired Student t test, 2-tailed, 95% CI, n = 50 pairs. P value for significance = 0.05. All of the measurements are reported in centimeters. GAD = gadolinium; ARR = anorectal ring; NS = not significant. Results are from paired Student t test, 2-tailed, 95% CI, n = 50 pairs. P value for significance = 0.05. All of the measurements are reported in centimeters. GAD = gadolinium; NS = not significant. a tending beyond the rectal wall (T2), whereas, without GAD, nonspecific spiculations penetrating the wall and extending into mesorectal fat (potential T3) could have represented either tumor or reactive changes. The lack of a gold standard limits our ability to prove this theory, but we know from the literature that radiologists tend to overstage tumor upwards of 43% of the time. 18 Treatment changes that would have occurred for the above downstaged cases consisted mainly of conversion from the need for neoadjuvant treatment to the lack thereof, appropriate for the new T stage.
Using a similar explanation for tumor relationships to anterior peritoneal reflection, ARR, and AV, although no statistical difference was shown with the use of GAD in 7 individual cases, by virtue of the enhancement/ de-enhancement phenomenon, an apparent change in relationship with these structures would have resulted in treatment changes in which greater distances of tumor from the AV or ARR would have allowed avoidance of preoperative CRT, used to downsize tumor and retract it from the internal anal sphincter. The critical assessment of the upper and lower tumor margins with respect to the anterior peritoneal reflection, ARR, and AV, absent in previous publications, can affect treatment more significantly than would small changes in the middle rectum.
Although tumor distances to these important anatomic landmarks were statistically smaller with GAD after neoadjuvant treatment, this would not have led to a change in treatment in any patient in our PNT cohort. This may have been because of our particular mix of patients, because several millimeters of difference in a tumor close to the sphincters could influence a surgeon's decision for sphincter preservation. We hypothesized that these shorter distances resulted from hyperenhancing radiated mucosa-mimicking tumor, which is known to become more permeable to flow. 5, 6 Also, in the PNT setting, there was little if any tumor left to be delineated by the washout de-enhanced appearance that we were able to appreciate at BL.
In concert with existing research that has demonstrated that GAD does not improve T-stage accuracy at BL staging MRI, 3, 4 our study supports that GAD does not alter the majority of patients' T stages and based on T-stage alone would not often alter therapy. However, unlike published literature, we went beyond T stage to assess other tumor features that are important for treatment planning. In addition, because restaging MRI has only recently become widespread, our study provides new data that would need additional validation.
There are numerous clinical implications of this study that might spur additional investigations, for example, the implication that a potentially smaller number of sphincter-preserving surgeries might be conducted with the implementation of GAD in PNT rectal MRI because the tumor seemed to be closer to the sphincters. Imaging is but one data point input to patient care, and it is important to acknowledge that the type of surgery performed depends on the clinical judgment of the surgeon at the time of surgery, during which alternate methods of assessing tumor location are used (eg, intraoperative endoscopy and digital examination). Imaging is important in determining which patients require neoadjuvant therapy and is a consideration in the decision to proceed with abdominoperineal resection versus low anterior resection. However, intraoperative localization of the tumor plays a larger role and remains the same, whether minimally invasive or open, because lesions are low enough to palpate with digital examination.
The limitations of this study are its retrospective nature and small sample size. Furthermore, our method of GAD use includes DCE-MRI, which was not widely used, and subsequent static GAD images. We also did not separately compare the effects of the static images and the DCE images on our tumor staging versus no GAD. A final limitation is the artificial assessment that our surgeon was able to conduct from only reading the clinical proforma that we provided in the absence of the critically valuable and more realistic input of a direct history and physical examination on the patient, supplemented by discussion of each patient's complexities in a multidisciplinary tumor board.
CONCLUSION
From our data, the effect of GAD on BL tumor interpretation could have potentially changed treatment in 24% of patients, mostly because of differences in tumor position with respect to critical anatomic landmarks (eg, ARR, AV, and anterior peritoneal reflection). In only a fraction of these cases would initial treatment recommendations have changed because of either unchanged N stage or lack of other pivotal differences to warrant a different treatment approach. In the postneoadjuvant setting, GAD resulted in statistically smaller distances between the lower tumor edge and the ARR and AV, which might suggest the potential for fewer sphincter-preserving operations when using GAD. However, in our particular pa- tients, this never led to a change in treatment planning, perhaps because of the chance location and distribution of tumors in our cohort. Given the theoretical and retrospective nature of our study, we believe that additional investigation into the value of GAD would have to be prospective but is unlikely to be pursued because of the safety profile, low cost, and overall acceptance of GAD. Finally, the question of GAD use may become less trivial if newly discovered toxicities, such as the recent revelation of GAD brain deposition, prove to confer long-term harm to patients.
